Adherence to clozapine vs. other antipsychotics in schizophrenia
Background To date, there have been no studies evaluating adherence to clozapine with electronic adherence monitoring (EAM) such as the Medication Event Monitoring System (MEMS®). Methods In outpatients with schizophrenia, we conducted a 3‐month prospective study investigating antipsychotic adherenc...
Saved in:
Published in | Acta Psychiatrica Scandinavica Vol. 142; no. 2; pp. 87 - 95 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Aalborg
Wiley
01.08.2020
Blackwell Publishing Ltd |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background
To date, there have been no studies evaluating adherence to clozapine with electronic adherence monitoring (EAM) such as the Medication Event Monitoring System (MEMS®).
Methods
In outpatients with schizophrenia, we conducted a 3‐month prospective study investigating antipsychotic adherence with EAM (eCAP®). Participants were treated with different oral antipsychotics, including clozapine, and blind to EAM monitoring; all were on antipsychotic monotherapy administered once daily. Outcome measures included adherence rate, missed dose, and medication gap. Adherence trajectory patterns were also analyzed for clozapine vs. other antipsychotics collectively.
Results
A total of 111 patients were included in the study; 33 and 78 patients received clozapine or other antipsychotics, respectively. Adherence rates, defined as proportion of days that the subject took the medication at the prescribed time ± 3 h and proportion of subjects with ≥80% adherence, were numerically higher in patients receiving clozapine vs. other antipsychotics (72.0% vs. 65.1%, P = 0.10; 49.5% vs. 35.7%, P = 0.11, respectively). Along similar lines, some of the missed dose and medication gap outcomes were significantly better in patients receiving clozapine vs. other antipsychotics. Three adherence trajectory patterns were identified for both clozapine and other antipsychotics, with two shared by both groups (i.e., low adherence with a slight decrease over time; high and stable adherence).
Conclusion
Findings suggest that in patients with schizophrenia clozapine adherence is at least comparable, if not slightly better, compared with other antipsychotics. |
---|---|
AbstractList | BackgroundTo date, there have been no studies evaluating adherence to clozapine with electronic adherence monitoring (EAM) such as the Medication Event Monitoring System (MEMS®).MethodsIn outpatients with schizophrenia, we conducted a 3‐month prospective study investigating antipsychotic adherence with EAM (eCAP®). Participants were treated with different oral antipsychotics, including clozapine, and blind to EAM monitoring; all were on antipsychotic monotherapy administered once daily. Outcome measures included adherence rate, missed dose, and medication gap. Adherence trajectory patterns were also analyzed for clozapine vs. other antipsychotics collectively.ResultsA total of 111 patients were included in the study; 33 and 78 patients received clozapine or other antipsychotics, respectively. Adherence rates, defined as proportion of days that the subject took the medication at the prescribed time ± 3 h and proportion of subjects with ≥80% adherence, were numerically higher in patients receiving clozapine vs. other antipsychotics (72.0% vs. 65.1%, P = 0.10; 49.5% vs. 35.7%, P = 0.11, respectively). Along similar lines, some of the missed dose and medication gap outcomes were significantly better in patients receiving clozapine vs. other antipsychotics. Three adherence trajectory patterns were identified for both clozapine and other antipsychotics, with two shared by both groups (i.e., low adherence with a slight decrease over time; high and stable adherence).ConclusionFindings suggest that in patients with schizophrenia clozapine adherence is at least comparable, if not slightly better, compared with other antipsychotics. To date, there have been no studies evaluating adherence to clozapine with electronic adherence monitoring (EAM) such as the Medication Event Monitoring System (MEMS® ).BACKGROUNDTo date, there have been no studies evaluating adherence to clozapine with electronic adherence monitoring (EAM) such as the Medication Event Monitoring System (MEMS® ).In outpatients with schizophrenia, we conducted a 3-month prospective study investigating antipsychotic adherence with EAM (eCAP® ). Participants were treated with different oral antipsychotics, including clozapine, and blind to EAM monitoring; all were on antipsychotic monotherapy administered once daily. Outcome measures included adherence rate, missed dose, and medication gap. Adherence trajectory patterns were also analyzed for clozapine vs. other antipsychotics collectively.METHODSIn outpatients with schizophrenia, we conducted a 3-month prospective study investigating antipsychotic adherence with EAM (eCAP® ). Participants were treated with different oral antipsychotics, including clozapine, and blind to EAM monitoring; all were on antipsychotic monotherapy administered once daily. Outcome measures included adherence rate, missed dose, and medication gap. Adherence trajectory patterns were also analyzed for clozapine vs. other antipsychotics collectively.A total of 111 patients were included in the study; 33 and 78 patients received clozapine or other antipsychotics, respectively. Adherence rates, defined as proportion of days that the subject took the medication at the prescribed time ± 3 h and proportion of subjects with ≥80% adherence, were numerically higher in patients receiving clozapine vs. other antipsychotics (72.0% vs. 65.1%, P = 0.10; 49.5% vs. 35.7%, P = 0.11, respectively). Along similar lines, some of the missed dose and medication gap outcomes were significantly better in patients receiving clozapine vs. other antipsychotics. Three adherence trajectory patterns were identified for both clozapine and other antipsychotics, with two shared by both groups (i.e., low adherence with a slight decrease over time; high and stable adherence).RESULTSA total of 111 patients were included in the study; 33 and 78 patients received clozapine or other antipsychotics, respectively. Adherence rates, defined as proportion of days that the subject took the medication at the prescribed time ± 3 h and proportion of subjects with ≥80% adherence, were numerically higher in patients receiving clozapine vs. other antipsychotics (72.0% vs. 65.1%, P = 0.10; 49.5% vs. 35.7%, P = 0.11, respectively). Along similar lines, some of the missed dose and medication gap outcomes were significantly better in patients receiving clozapine vs. other antipsychotics. Three adherence trajectory patterns were identified for both clozapine and other antipsychotics, with two shared by both groups (i.e., low adherence with a slight decrease over time; high and stable adherence).Findings suggest that in patients with schizophrenia clozapine adherence is at least comparable, if not slightly better, compared with other antipsychotics.CONCLUSIONFindings suggest that in patients with schizophrenia clozapine adherence is at least comparable, if not slightly better, compared with other antipsychotics. Background To date, there have been no studies evaluating adherence to clozapine with electronic adherence monitoring (EAM) such as the Medication Event Monitoring System (MEMS®). Methods In outpatients with schizophrenia, we conducted a 3‐month prospective study investigating antipsychotic adherence with EAM (eCAP®). Participants were treated with different oral antipsychotics, including clozapine, and blind to EAM monitoring; all were on antipsychotic monotherapy administered once daily. Outcome measures included adherence rate, missed dose, and medication gap. Adherence trajectory patterns were also analyzed for clozapine vs. other antipsychotics collectively. Results A total of 111 patients were included in the study; 33 and 78 patients received clozapine or other antipsychotics, respectively. Adherence rates, defined as proportion of days that the subject took the medication at the prescribed time ± 3 h and proportion of subjects with ≥80% adherence, were numerically higher in patients receiving clozapine vs. other antipsychotics (72.0% vs. 65.1%, P = 0.10; 49.5% vs. 35.7%, P = 0.11, respectively). Along similar lines, some of the missed dose and medication gap outcomes were significantly better in patients receiving clozapine vs. other antipsychotics. Three adherence trajectory patterns were identified for both clozapine and other antipsychotics, with two shared by both groups (i.e., low adherence with a slight decrease over time; high and stable adherence). Conclusion Findings suggest that in patients with schizophrenia clozapine adherence is at least comparable, if not slightly better, compared with other antipsychotics. |
Author | Carol Borlido Gary Remington Marcos Sanches Hiroyoshi Takeuchi Ofer Agid Lillian Harber Celine Teo |
Author_xml | – sequence: 1 givenname: H. orcidid: 0000-0002-8844-4786 surname: Takeuchi fullname: Takeuchi, H. organization: Centre for Addiction and Mental Health – sequence: 2 givenname: C. surname: Borlido fullname: Borlido, C. organization: Centre for Addiction and Mental Health – sequence: 3 givenname: M. surname: Sanches fullname: Sanches, M. organization: Centre for Addiction and Mental Health – sequence: 4 givenname: C. surname: Teo fullname: Teo, C. organization: Centre for Addiction and Mental Health – sequence: 5 givenname: L. surname: Harber fullname: Harber, L. organization: Centre for Addiction and Mental Health – sequence: 6 givenname: O. surname: Agid fullname: Agid, O. organization: University of Toronto – sequence: 7 givenname: G. orcidid: 0000-0001-9433-9416 surname: Remington fullname: Remington, G. email: Gary.Remington@camh.ca organization: Centre for Addiction and Mental Health |
BackLink | https://cir.nii.ac.jp/crid/1872272492558869760$$DView record in CiNii |
BookMark | eNp9kF1LwzAUhoMoOOdu_AUFvRChM0nzeecYfsFAQQXvSpqmNNIltemU7debWb0ZYi5OSM7zHA7vEdh33hkAThCcongulW7DFGUYij0wQgzCFBLC98EIQohSJuHrIZiEYIv4hFIIJEfgalbWpjNOm6T3iW78RrXWmeQjTBPfx1aiXG_bsNa1760OiXVJ0LXd-LaOmlXH4KBSTTCTn3sMXm6un-d36eLh9n4-W6SaYClSVpSVkSXjFa04r8qCF6QSGBdUS1UyyjTnmmKDSyglxZjxIn4WspRRo6LKxuB8mNt2_n1lQp8vbdCmaZQzfhVyTDBkGeaER_R0B33zq87F7SKVUYgYYyRScKB050PoTJVr26veetd3yjY5gvk21Xybav6dalQudpS2s0vVrf-G0QB_2sas_yHz2fzx6dc5GxxnbVxnW5HgGHNMJKZUCCY5g9kXaAKTrg |
CitedBy_id | crossref_primary_10_1111_acps_13394 crossref_primary_10_1016_j_schres_2023_07_002 crossref_primary_10_1186_s12888_021_03037_0 crossref_primary_10_1016_j_schres_2021_07_024 crossref_primary_10_1097_JCP_0000000000001804 crossref_primary_10_2147_PPA_S495254 crossref_primary_10_1177_0004867421998800 crossref_primary_10_1177_20451253211032053 crossref_primary_10_1016_j_schres_2023_06_005 crossref_primary_10_1080_08039488_2022_2160878 crossref_primary_10_1016_j_schres_2021_08_017 crossref_primary_10_1016_j_schres_2023_11_010 crossref_primary_10_1016_j_schres_2022_08_013 crossref_primary_10_1093_schbul_sbab103 crossref_primary_10_2147_NDT_S402945 crossref_primary_10_1016_j_schres_2022_07_014 crossref_primary_10_1111_acps_13411 crossref_primary_10_1093_schizbullopen_sgab048 crossref_primary_10_3389_fpsyt_2022_1021780 crossref_primary_10_7759_cureus_25765 crossref_primary_10_1136_bmjopen_2024_085956 crossref_primary_10_1016_j_euroneuro_2024_04_012 crossref_primary_10_1192_bjp_2022_1 crossref_primary_10_1097_JCP_0000000000001673 crossref_primary_10_1097_JCP_0000000000001671 |
Cites_doi | 10.1016/j.schres.2006.11.015 10.2147/NDT.S39303 10.4088/JCP.v65n0311 10.1097/YIC.0000000000000188 10.1192/bjp.156.6.798 10.1016/j.schres.2013.02.016 10.4088/JCP.v69n0107 10.1016/j.schres.2005.10.015 10.1016/j.schres.2017.06.026 10.1176/appi.ajp.158.8.1305 10.1016/j.ijcard.2016.04.082 10.1093/schbul/sbj067 10.1001/archpsyc.1988.01800330013001 10.1038/clpt.2014.59 10.1016/j.psychres.2004.11.002 10.1176/ajp.2006.163.4.600 10.1016/j.schres.2008.09.007 10.1007/s40263-020-00713-9 10.1176/appi.ajp.158.4.518 10.1177/2045125312474019 10.2147/PPA.S124658 10.18553/jmcp.2016.22.11.1349 10.1016/j.schres.2011.11.008 10.1017/S0033291700050182 10.1176/ps.2007.58.9.1187 10.1176/appi.ps.55.8.886 10.1592/phco.2005.25.9.1242 10.1016/j.psychres.2014.11.002 10.1016/j.psychres.2019.01.110 |
ContentType | Journal Article |
Copyright | 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd 2020 John Wiley & Sons A/S 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
Copyright_xml | – notice: 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd – notice: 2020 John Wiley & Sons A/S – notice: 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
DBID | RYH AAYXX CITATION 7TK K9. 7X8 |
DOI | 10.1111/acps.13208 |
DatabaseName | CiNii Complete CrossRef Neurosciences Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | CrossRef ProQuest Health & Medical Complete (Alumni) Neurosciences Abstracts MEDLINE - Academic |
DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1600-0447 |
EndPage | 95 |
ExternalDocumentID | 10_1111_acps_13208 ACPS13208 |
Genre | article |
GrantInformation_xml | – fundername: Canadian Institutes of Health Research funderid: 201011 |
GroupedDBID | --- -~X .3N .GA 05W 0R~ 10A 1OC 23M 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 5GY 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABIVO ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFS ACGOF ACHQT ACMXC ACPOU ACPRK ACUHS ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUYR AEYWJ AFBPY AFEBI AFFPM AFGKR AFWVQ AFZJQ AGHNM AGYGG AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DUUFO EAD EAP EAS EBC EBD EBS EMB EMK EMOBN EPS ESX EX3 F00 F01 F04 F5P FUBAC FZ0 G-S GODZA H.X HGLYW HZI HZ~ IHE IX1 J0M K48 KBYEO L7B LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 R.K ROL RX1 RYH SUPJJ SV3 TEORI TUS UB1 UPT V9Y W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WVDHM WXI WXSBR XG1 YF5 ZZTAW ~IA ~WT .55 .GJ .Y3 1OB 31~ 3O- 53G AANHP ABEML ACBWZ ACRPL ACSCC ACYXJ ADNMO AEUQT AFFNX AFPWT AHEFC ASPBG AVWKF AZFZN CAG COF EJD FEDTE HF~ HVGLF LW6 OHT PALCI RIWAO RJQFR SAMSI WRC WUP X7M ZGI ZXP AAYXX AGQPQ CITATION 7TK AAMMB AEFGJ AGXDD AIDQK AIDYY K9. 7X8 |
ID | FETCH-LOGICAL-c4298-6bdfe9d67f5f77fdb7b4f822b5c9ad656c77c52e2d09952267b656b9d9fe958f3 |
IEDL.DBID | DR2 |
ISSN | 0001-690X 1600-0447 |
IngestDate | Fri Jul 11 10:58:39 EDT 2025 Wed Aug 13 04:51:21 EDT 2025 Thu Apr 24 23:04:25 EDT 2025 Tue Jul 01 01:06:48 EDT 2025 Wed Jan 22 16:33:29 EST 2025 Thu Jun 26 22:57:17 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4298-6bdfe9d67f5f77fdb7b4f822b5c9ad656c77c52e2d09952267b656b9d9fe958f3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
ORCID | 0000-0002-8844-4786 0000-0001-9433-9416 |
PQID | 2435016664 |
PQPubID | 33508 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_2420632747 proquest_journals_2435016664 crossref_citationtrail_10_1111_acps_13208 crossref_primary_10_1111_acps_13208 wiley_primary_10_1111_acps_13208_ACPS13208 nii_cinii_1872272492558869760 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2020-08-01 August 2020 2020-08-00 20200801 |
PublicationDateYYYYMMDD | 2020-08-01 |
PublicationDate_xml | – month: 08 year: 2020 text: 2020-08-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Aalborg |
PublicationPlace_xml | – name: Aalborg |
PublicationTitle | Acta Psychiatrica Scandinavica |
PublicationYear | 2020 |
Publisher | Wiley Blackwell Publishing Ltd |
Publisher_xml | – name: Wiley – name: Blackwell Publishing Ltd |
References | 2004; 65 2015; 225 2005; 133 2006; 32 1976 2009 2007; 90 2013; 146 2020; 34 1983; 13 2007; 58 2013; 9 2005; 25 2006; 82 1998; 59 2004; 55 2018; 193 2020; 3 2012; 134 2001 2000 2017; 11 2017; 32 2006; 163 2008; 69 1988; 45 2016; 216 2009; 107 1990; 156 2014; 95 2001; 158 2019; 275 2016; 22 e_1_2_9_30_1 Guy W (e_1_2_9_24_1) 1976 e_1_2_9_31_1 e_1_2_9_11_1 e_1_2_9_34_1 e_1_2_9_10_1 Bellack AS (e_1_2_9_28_1) 2009 e_1_2_9_35_1 e_1_2_9_13_1 e_1_2_9_32_1 e_1_2_9_12_1 e_1_2_9_33_1 Sheehan DV (e_1_2_9_22_1) 1998; 59 e_1_2_9_15_1 e_1_2_9_14_1 e_1_2_9_17_1 e_1_2_9_16_1 e_1_2_9_19_1 e_1_2_9_18_1 e_1_2_9_20_1 e_1_2_9_21_1 e_1_2_9_8_1 e_1_2_9_7_1 e_1_2_9_6_1 e_1_2_9_5_1 e_1_2_9_4_1 Appelbaum PS (e_1_2_9_23_1) 2001 e_1_2_9_3_1 e_1_2_9_2_1 e_1_2_9_9_1 e_1_2_9_26_1 e_1_2_9_25_1 e_1_2_9_27_1 e_1_2_9_29_1 |
References_xml | – volume: 216 start-page: 104 year: 2016 end-page: 109 article-title: Impact of once‐ or twice‐daily dosing frequency on adherence to chronic cardiovascular disease medications: a meta‐regression analysis publication-title: Int J Cardiol – volume: 59 start-page: 22 year: 1998 end-page: 33 article-title: The mini‐international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM‐IV and ICD‐10 publication-title: J Clin Psychiatry – volume: 146 start-page: 196 year: 2013 end-page: 200 article-title: Antipsychotic treatment dosing profile in patients with schizophrenia evaluated with electronic monitoring (MEMS®) publication-title: Schizophr Res – volume: 32 start-page: 715 year: 2006 end-page: 723 article-title: Randomized controlled trial of effect of prescription of clozapine versus other second‐generation antipsychotic drugs in resistant schizophrenia publication-title: Schizophr Bull – volume: 158 start-page: 1305 year: 2001 end-page: 1313 article-title: A double‐blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia publication-title: Am J Psychiatry – year: 2001 – volume: 225 start-page: 14 year: 2015 end-page: 30 article-title: A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia‐spectrum disorders publication-title: Psychiatry Res – start-page: 1 year: 2009 end-page: 48 article-title: The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness publication-title: J Clin Psychiatry – year: 2000 – volume: 133 start-page: 129 year: 2005 end-page: 133 article-title: A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia publication-title: Psychiatry Res – volume: 90 start-page: 229 year: 2007 end-page: 237 article-title: The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia publication-title: Schizophr Res – volume: 69 start-page: 47 year: 2008 end-page: 53 article-title: A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia publication-title: J Clin Psychiatry – volume: 65 start-page: 354 year: 2004 end-page: 360 article-title: Adherence to conventional and atypical antipsychotics after hospital discharge publication-title: J Clin Psychiatry – volume: 275 start-page: 149 year: 2019 end-page: 154 article-title: Reasons for clozapine discontinuation in patients with treatment‐resistant schizophrenia publication-title: Psychiatry Res – volume: 156 start-page: 798 year: 1990 end-page: 808 article-title: Insight and psychosis publication-title: Br J Psychiatry – volume: 134 start-page: 226 year: 2012 end-page: 231 article-title: Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia publication-title: Schizophr Res – volume: 193 start-page: 114 year: 2018 end-page: 118 article-title: Evaluation of adherence patterns in schizophrenia using electronic monitoring (MEMS®): a six‐month post‐discharge prospective study publication-title: Schizophr Res – volume: 45 start-page: 789 year: 1988 end-page: 796 article-title: Clozapine for the treatment‐resistant schizophrenic. A double‐blind comparison with chlorpromazine publication-title: Arch Gen Psychiatry – volume: 11 start-page: 449 year: 2017 end-page: 468 article-title: Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness publication-title: Patient Prefer Adherence – volume: 55 start-page: 886 year: 2004 end-page: 891 article-title: Partial compliance and risk of rehospitalization among California medicaid patients with schizophrenia publication-title: Psychiatr Serv – volume: 107 start-page: 213 year: 2009 end-page: 217 article-title: Evaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS®) and its relationship to sociodemographic, clinical and psychopathological variables publication-title: Schizophr Res – volume: 58 start-page: 1187 year: 2007 end-page: 1192 article-title: Relationships among subjective and objective measures of adherence to oral antipsychotic medications publication-title: Psychiatr Serv – volume: 32 start-page: 337 year: 2017 end-page: 342 article-title: Patient attitudes to clozapine initiation publication-title: Int Clin Psychopharmacol – volume: 9 start-page: 119 year: 2013 end-page: 131 article-title: Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta‐analysis publication-title: Neuropsychiatr Dis Treat – volume: 82 start-page: 107 year: 2006 end-page: 114 article-title: Electronically monitored adherence in outpatients with schizophrenia or schizoaffective disorder: a comparison of first‐ vs. second‐generation antipsychotics publication-title: Schizophr Res – volume: 95 start-page: 617 year: 2014 end-page: 626 article-title: Methods for measuring, enhancing, and accounting for medication adherence in clinical trials publication-title: Clin Pharmacol Ther – volume: 158 start-page: 518 year: 2001 end-page: 526 article-title: Effectiveness of second‐generation antipsychotics in patients with treatment‐resistant schizophrenia: a review and meta‐analysis of randomized trials publication-title: Am J Psychiatry – volume: 22 start-page: 1349 year: 2016 end-page: 1361 article-title: Patterns of adherence to oral atypical antipsychotics among patients diagnosed with schizophrenia publication-title: J Manag Care Spec Pharm – year: 1976 – volume: 25 start-page: 1242 year: 2005 end-page: 1247 article-title: Drug adherence: effects of decreased visit frequency on adherence to clozapine therapy publication-title: Pharmacotherapy – volume: 163 start-page: 600 year: 2006 end-page: 610 article-title: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment publication-title: Am J Psychiatry – volume: 13 start-page: 177 year: 1983 end-page: 183 article-title: A self‐report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity publication-title: Psychol Med – volume: 3 start-page: 200 year: 2020 end-page: 218 article-title: Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review publication-title: Ther Adv Psychopharmacol – volume: 34 start-page: 579 year: 2020 end-page: 598 article-title: Adherence to oral antipsychotics measured by electronic adherence monitoring in schizophrenia: a systematic review and meta‐analysis publication-title: CNS Drugs – ident: e_1_2_9_12_1 doi: 10.1016/j.schres.2006.11.015 – ident: e_1_2_9_25_1 – ident: e_1_2_9_34_1 doi: 10.2147/NDT.S39303 – ident: e_1_2_9_8_1 doi: 10.4088/JCP.v65n0311 – volume-title: MacArthur competence assessment tool for clinical research (MacCAT‐CR) year: 2001 ident: e_1_2_9_23_1 – ident: e_1_2_9_20_1 doi: 10.1097/YIC.0000000000000188 – ident: e_1_2_9_27_1 doi: 10.1192/bjp.156.6.798 – ident: e_1_2_9_32_1 doi: 10.1016/j.schres.2013.02.016 – volume-title: ECDEU assessment manual for psychopharmacology year: 1976 ident: e_1_2_9_24_1 – ident: e_1_2_9_30_1 doi: 10.4088/JCP.v69n0107 – ident: e_1_2_9_13_1 doi: 10.1016/j.schres.2005.10.015 – ident: e_1_2_9_11_1 doi: 10.1016/j.schres.2017.06.026 – ident: e_1_2_9_16_1 doi: 10.1176/appi.ajp.158.8.1305 – ident: e_1_2_9_33_1 doi: 10.1016/j.ijcard.2016.04.082 – ident: e_1_2_9_18_1 doi: 10.1093/schbul/sbj067 – volume: 59 start-page: 22 year: 1998 ident: e_1_2_9_22_1 article-title: The mini‐international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM‐IV and ICD‐10 publication-title: J Clin Psychiatry – ident: e_1_2_9_15_1 doi: 10.1001/archpsyc.1988.01800330013001 – ident: e_1_2_9_5_1 doi: 10.1038/clpt.2014.59 – ident: e_1_2_9_7_1 doi: 10.1016/j.psychres.2004.11.002 – ident: e_1_2_9_19_1 doi: 10.1176/ajp.2006.163.4.600 – ident: e_1_2_9_6_1 doi: 10.1016/j.schres.2008.09.007 – ident: e_1_2_9_14_1 doi: 10.1007/s40263-020-00713-9 – ident: e_1_2_9_17_1 doi: 10.1176/appi.ajp.158.4.518 – ident: e_1_2_9_2_1 doi: 10.1177/2045125312474019 – start-page: 1 year: 2009 ident: e_1_2_9_28_1 article-title: The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness publication-title: J Clin Psychiatry – ident: e_1_2_9_4_1 doi: 10.2147/PPA.S124658 – ident: e_1_2_9_35_1 doi: 10.18553/jmcp.2016.22.11.1349 – ident: e_1_2_9_10_1 doi: 10.1016/j.schres.2011.11.008 – ident: e_1_2_9_26_1 doi: 10.1017/S0033291700050182 – ident: e_1_2_9_9_1 doi: 10.1176/ps.2007.58.9.1187 – ident: e_1_2_9_29_1 doi: 10.1176/appi.ps.55.8.886 – ident: e_1_2_9_31_1 doi: 10.1592/phco.2005.25.9.1242 – ident: e_1_2_9_3_1 doi: 10.1016/j.psychres.2014.11.002 – ident: e_1_2_9_21_1 doi: 10.1016/j.psychres.2019.01.110 |
SSID | ssib001098819 ssj0005108 ssib020716634 ssib053816035 ssib002667577 ssib006541434 ssib053816034 ssib006541432 ssib006541433 ssib017358148 ssib058492090 ssib000381225 |
Score | 2.4480522 |
Snippet | Background
To date, there have been no studies evaluating adherence to clozapine with electronic adherence monitoring (EAM) such as the Medication Event... BackgroundTo date, there have been no studies evaluating adherence to clozapine with electronic adherence monitoring (EAM) such as the Medication Event... To date, there have been no studies evaluating adherence to clozapine with electronic adherence monitoring (EAM) such as the Medication Event Monitoring System... |
SourceID | proquest crossref wiley nii |
SourceType | Aggregation Database Enrichment Source Index Database Publisher |
StartPage | 87 |
SubjectTerms | adherence Adult Antipsychotic Agents Antipsychotics Clozapine compliance Female Humans Male Medication Adherence Mental disorders Microelectromechanical systems Outpatients Prospective Studies Psychotropic drugs Schizophrenia |
Title | Adherence to clozapine vs. other antipsychotics in schizophrenia |
URI | https://cir.nii.ac.jp/crid/1872272492558869760 https://onlinelibrary.wiley.com/doi/abs/10.1111%2Facps.13208 https://www.proquest.com/docview/2435016664 https://www.proquest.com/docview/2420632747 |
Volume | 142 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dS-QwEB_8APHF8_zAeioRfVHoss0mTQs-uHq3iKCIH7AvUpK0xeLSXeyuD_71zvRjXQ8R7l5KaSYlzWSS3zTzmwAcekRf9LVwcWlJXBF7aFJKCFcqmwSprzxpie98de1fPIjLvuzPwUnDhanyQ0x_uJFllPM1Gbg2xYyRazsqWkQAJqYvBWsRIrr9yB2Fg62ahtFfRhewX-cmpTCej6qfVqP5PMs-Ac1ZuFquN70f8Ni0tAozeW5NxqZl3_5K4vi_n7IKKzUQZd1q5PyEuSRfg6Wreqt9HU678VNFBWTjIbOD4ZseYQF7LVqsZG0x1ElWk7gyW7AsZ8VsBN8GPPT-3J9fuPVxC67FRSlwfROnSRj7KpWpUmlslBEp4gcjbahjxH1WKSt5wmNElQTblMGHJoxDrCaDtLMJC_kwT7aA8UB3uG2H3DNSqLaHrzLKcm07OkQPKnXgqOn2yNa5yOlIjEHU-CTUJVHZJQ4cTGVHVQaOL6V2UXv4Mrp6geJcUS5EKYPAR8TVdmCn0WtUW2kRcUHbqujACQf2p8VoX7RpovNkOCEZjiiOfHcHjkslftOKqHt-c1febf-L8C9Y5uTGl3GFO7Awfpkku4h1xmYPFrtnv896e-XYfge0B_e7 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fT9swED4NkICXARto2Sh42l5AStW4dpy8rSpUhVGEBkh9i2InEdFQWpGWB_567pz0BwhNYi9RFJ-jxOezv7PvPgP89Ch90Y-Fi1NL6orEQ5NSQrhSmTTIfOVJQ_nOg0u_fyvOh3JYx-ZQLkzFDzFfcCPLsOM1GTgtSC9ZeWzGZZMygIMVWKMjvYk6_-TPgj0Ku1s1EKPHjE7gsGYnpUCeRd0X89FKkecvoOYyYLUzTm-rOla1tESFFGjytzmd6KZ5ekXj-N8_sw0fayzKOlXn2YEPafEJ1gf1bvtn-NVJ7qpsQDYZMXM_eorHWMAeyyaziVsM1ZLXeVy5KVlesHI5iG8XbnunN92-W5-44BqclwLX10mWhomvMpkplSVaaZEhhNDShHGC0M8oZSRPeYLAkpCb0vhQh0mI1WSQtfdgtRgV6RdgPIjb3LRC7mkpVMvDV2lleGzacYhOVObA0azdI1PTkdOpGPfRzC2hJolskzjwYy47rkg43pRqoPrwZXT1AsW5IjpEKYPAR9DVcmB_ptioNtQy4oJ2VtGHEw58nxejidG-SVykoynJcARy5L47cGy1-I-viDrdq2t79_U9woew0b8ZXEQXZ5e_v8EmJ6_ehhnuw-rkYZo2EPpM9IHt4M9oCPpl |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED_aDkpf1m1dqbe01WhfNnCIFcmyoQ8LbUP30VL6AXkZxpIsZlacMCd9yF_fO3-k6SiD7cUY6yRknU73O-nuBHAYUPhimAofVUvmCxugSCkhfKlMFrlQBdJQvPP5RXh2K76O5GgFjtpYmDo_xGLDjSSjWq9JwCfWLQl5aiZllwKAo1V4IcJeTBc3nFw9Jo_C2Vavw2gwow04apKTkh_PY90n6mi1yPMnSHMZr1YKZ7gJP9qu1n4mv7qzqe6a-R9ZHP_3X17BywaJskE9dV7DSla8gfXz5qx9Cz4P7M86FpBNx8zcjefpBAvYfdllVdgWQ6bkTRRXbkqWF6xcduF7C7fD05vjM7-5b8E3qJUiP9TWZbENlZNOKWe10sIhgNDSxKlF4GeUMpJn3CKsJNymNH7UsY2xmoxcfxvWinGR7QDjUdrnphfzQEuhegE2pZXhqemnMZpQzoOP7bAnpklGTndi3CWtUUJDklRD4sHBgnZSp-B4lmoXuYeN0TOIFOeKkiFKGUUhQq6eB52Wr0kjpmXCBZ2rogUnPPiwKEYBo1OTtMjGM6LhCOPIePfgU8XEv_QiGRxfXldv7_6FeB_WL0-GyfcvF9_ewwYnk77yMezA2vT3LNtF3DPVe9X0fgB5rPkU |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Adherence+to+clozapine+vs.+other+antipsychotics+in+schizophrenia&rft.jtitle=Acta+psychiatrica+Scandinavica&rft.au=Takeuchi%2C+H.&rft.au=Borlido%2C+C.&rft.au=Sanches%2C+M.&rft.au=Teo%2C+C.&rft.date=2020-08-01&rft.issn=0001-690X&rft.eissn=1600-0447&rft.volume=142&rft.issue=2&rft.spage=87&rft.epage=95&rft_id=info:doi/10.1111%2Facps.13208&rft.externalDBID=10.1111%252Facps.13208&rft.externalDocID=ACPS13208 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0001-690X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0001-690X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0001-690X&client=summon |